Part I . Overview We are a global performance beauty company delivering breakthrough products with a customer-centric approach. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-03 | 2025-12-31 | 0001628280-26-014001 | EDGAR | 64K words |
| 2025-03-04 | 2024-12-31 | 0001570562-25-000020 | EDGAR | — |
| 2024-03-07 | 2023-12-31 | 0001570562-24-000041 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001570562-23-000038 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001570562-22-000067 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001570562-21-000093 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001570562-20-000061 | EDGAR | — |
| 2019-03-20 | 2018-12-31 | 0001570562-19-000038 | EDGAR | — |
| 2018-03-29 | 2017-12-31 | 0001570562-18-000013 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001628280-25-049673 | EDGAR | 47K words |
| 2025-08-05 | 2025-06-30 | 0001570562-25-000098 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001570562-25-000075 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001570562-24-000128 | EDGAR | — |
| 2024-07-31 | 2024-06-30 | 0001570562-24-000116 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001570562-24-000080 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001570562-23-000115 | EDGAR | — |
| 2023-08-02 | 2023-06-30 | 0001570562-23-000088 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001570562-23-000070 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001570562-22-000143 | EDGAR | — |
| 2022-08-02 | 2022-06-30 | 0001570562-22-000119 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001570562-22-000102 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-13 | 0001570562-26-000043 | EDGAR | 1K words |
| 2026-03-03 | 0001628280-26-013872 | EDGAR | — |
| 2026-01-09 | 0001570562-26-000003 | EDGAR | — |
| 2025-11-05 | 0001628280-25-049564 | EDGAR | — |
| 2025-09-08 | 0001570562-25-000110 | EDGAR | — |
| 2025-08-05 | 0001570562-25-000094 | EDGAR | — |
| 2025-06-06 | 0001570562-25-000085 | EDGAR | — |
| 2025-05-27 | 0001570562-25-000083 | EDGAR | — |
| 2025-05-07 | 0001570562-25-000074 | EDGAR | — |
| 2025-05-05 | 0001570562-25-000069 | EDGAR | — |
153 total filings indexed. 122 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001570562 |
| Ticker | EOLS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.evolus.com |
| Listed | 2018-02-08 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report